Day One Biopharmaceuticals, Inc. (DAWN): Price and Financial Metrics
GET POWR RATINGS... FREE!
DAWN Stock Price Chart Interactive Chart >
DAWN Price/Volume Stats
| Current price | $21.11 | 52-week high | $28.35 |
| Prev. close | $21.75 | 52-week low | $5.44 |
| Day low | $20.92 | Volume | 434,200 |
| Day high | $21.98 | Avg. volume | 666,296 |
| 50-day MA | $21.35 | Dividend yield | N/A |
| 200-day MA | $18.33 | Market Cap | 1.55B |
Day One Biopharmaceuticals, Inc. (DAWN) Company Bio
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Latest DAWN News From Around the Web
Below are the latest news stories about DAY ONE BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate DAWN as an investment opportunity.
Thinking about buying stock in Duck Creek Technologies, CureVac, Day One Biopharmaceuticals, Bed Bath & Beyond, or Ocugen?NEW YORK , Jan. 9, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DCT, CVAC, DAWN, BBBY, and OCGN. … Full story available on Benzinga.com |
DAWN Rises on Promising Data in Brain Tumor StudyShares of Day One Biopharmaceuticals (NASDAQ:DAWN) are rising higher today after the company announced promising topline data from a Phase 2 study … |
Day One Biopharma Shares Rise 13% After Positive Topline Results for TovorafenibBy Chris Wack Day One Biopharmaceuticals Inc. shares were up 13% to $24.11 after the company said it saw positive topline results from an ongoing Phase 2… |
Day One stock surges 20% as brain tumor drug shows promise in mid-stage studyDay One Biopharmaceuticals (DAWN) reported data from an ongoing phase 2 trial of tovorafenib to treat recurrent or progressive pediatric low-grade glioma (pLGG).The main goal of the… |
Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging ResponsesDay One Biopharmaceuticals (NASDAQ: DAWN) announced topline results from the ongoing Phase 2 FIREFLY-1 trial evaluating tovorafenib (DAY101) as a monotherapy in recurrent or progressive pediatric low-grade glioma (pLGG). Pediatric low-grade glioma is the most common brain tumor diagnosed in children. Additional data will be submitted for presentation at an upcoming medical meeting in the second quarter of 2023. Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% were observ |
DAWN Price Returns
| 1-mo | -1.08% |
| 3-mo | 8.37% |
| 6-mo | -7.21% |
| 1-year | 53.64% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -1.91% |
| 2022 | 27.72% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...